IL288655A - Preparations and methods for the treatment of central nervous system disorders - Google Patents
Preparations and methods for the treatment of central nervous system disordersInfo
- Publication number
- IL288655A IL288655A IL288655A IL28865521A IL288655A IL 288655 A IL288655 A IL 288655A IL 288655 A IL288655 A IL 288655A IL 28865521 A IL28865521 A IL 28865521A IL 288655 A IL288655 A IL 288655A
- Authority
- IL
- Israel
- Prior art keywords
- compositions
- methods
- nervous system
- central nervous
- system disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Otolaryngology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962858621P | 2019-06-07 | 2019-06-07 | |
| PCT/US2020/031217 WO2020247127A1 (en) | 2019-06-07 | 2020-05-02 | Compositions and methods for treating central nervous system disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL288655A true IL288655A (en) | 2022-02-01 |
Family
ID=73652889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL288655A IL288655A (en) | 2019-06-07 | 2021-12-02 | Preparations and methods for the treatment of central nervous system disorders |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220226268A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3979985A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7749169B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN114340597B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020288999A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3142842A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL288655A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020247127A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021319064A1 (en) * | 2020-07-29 | 2023-03-23 | Perfect Daylight Limited | Methods of manufacture of suramin |
| US20230390223A1 (en) * | 2020-10-22 | 2023-12-07 | Paxmedica, Inc. | Administration of antipurinergic compositions for treating nervous system disorders |
| EP4229035A4 (en) * | 2020-10-22 | 2024-07-31 | Paxmedica, Inc. | INTRANASALY ADMINISTRATION OF SURAMIN FOR THE TREATMENT OF NERVOUS SYSTEM DISEASES |
| JP2024532288A (ja) * | 2021-08-23 | 2024-09-05 | パックスメディカ, インコーポレイテッド | 抗プリン作動薬を用いて神経系障害を処置するための方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5012285A (en) * | 1984-10-12 | 1986-05-02 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Use of suramin for clinical treatment of infection with any of the members of the family of human t-cell leukemia (htlv) viruses including lymphadenopathy virus (lav) |
| JP2003506458A (ja) * | 1999-08-11 | 2003-02-18 | ジョセフ ピサ, | シクロデキストリン誘導体の包接複合体形成の増強 |
| JP2005519075A (ja) * | 2002-02-25 | 2005-06-30 | リフジャスロウン エイチエフ | 吸収促進剤 |
| FR2867682B1 (fr) * | 2004-03-22 | 2009-06-05 | Galderma Res & Dev | Composition pharmaceutique anhydre associant un agent silicone et un principe actif solubilise. |
| US20070292523A1 (en) * | 2004-09-27 | 2007-12-20 | Joey Moodley | Dihydropyrimidine Formulations |
| JP2009530385A (ja) | 2006-03-22 | 2009-08-27 | マウント シナイ スクール オブ メディシン | うつ病の治療のためのケタミンの鼻内投与 |
| FR2912591B1 (fr) * | 2007-02-12 | 2009-05-01 | Oberthur Card Syst Sa | Procede et dispositif pour controler l'execution d'au moins une fonction dans un module de communication sans fil de courte portee d'un appareil mobile. |
| AR062239A1 (es) * | 2007-08-07 | 2008-10-22 | Civil De Estudios Superiores A | Composicion farmaceutica sinergica util para inhibir la neovascularizacion (angiogenesis) corneal y retinal, y de otros organos, en un humano o animal |
| US20120070487A1 (en) * | 2010-03-24 | 2012-03-22 | Aegis Therapeutics Llc | Alkylsaccharide compositions with nutraceuticals |
| GB201401904D0 (en) * | 2014-02-04 | 2014-03-19 | Ziarco Pharma Ltd | Pharmaceutical composition for topical administration |
| FR3025110B1 (fr) * | 2014-09-02 | 2016-12-23 | Univ Francois-Rabelais De Tours | Dispositif de pulverisation nasale de produit fluide |
| CN108024997A (zh) * | 2015-07-17 | 2018-05-11 | 奥维德医疗公司 | 用加波沙朵治疗发育障碍的方法 |
| HRP20250215T1 (hr) * | 2016-04-12 | 2025-06-20 | Tonix Pharma Limited | Formulacije oksitocina koje sadrže magnezij i postupci upotrebe |
| WO2018013811A1 (en) * | 2016-07-14 | 2018-01-18 | The Regents Of The University Of California | Diagnostic and methods of treatment for chronic fatigue syndrome and autism spectrum disorders |
| WO2018148262A1 (en) * | 2017-02-08 | 2018-08-16 | Csp Pharma, Inc. | Antipurinergic compounds and uses thereof |
| WO2018148580A1 (en) * | 2017-02-09 | 2018-08-16 | Perfect Daylight Limited | Methods for autism spectrum disorder pharmacotherapy |
| US11110060B2 (en) * | 2017-10-25 | 2021-09-07 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions and methods for delivering pharmaceutical agents |
-
2020
- 2020-05-02 JP JP2021572548A patent/JP7749169B2/ja active Active
- 2020-05-02 WO PCT/US2020/031217 patent/WO2020247127A1/en not_active Ceased
- 2020-05-02 US US17/615,673 patent/US20220226268A1/en not_active Abandoned
- 2020-05-02 EP EP20818146.1A patent/EP3979985A4/en active Pending
- 2020-05-02 CN CN202080055332.3A patent/CN114340597B/zh active Active
- 2020-05-02 CA CA3142842A patent/CA3142842A1/en active Pending
- 2020-05-02 AU AU2020288999A patent/AU2020288999A1/en not_active Abandoned
-
2021
- 2021-12-02 IL IL288655A patent/IL288655A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20220226268A1 (en) | 2022-07-21 |
| EP3979985A4 (en) | 2023-05-03 |
| CA3142842A1 (en) | 2020-12-10 |
| JP2022535920A (ja) | 2022-08-10 |
| WO2020247127A1 (en) | 2020-12-10 |
| EP3979985A1 (en) | 2022-04-13 |
| AU2020288999A1 (en) | 2022-02-03 |
| CN114340597B (zh) | 2025-01-28 |
| CN114340597A (zh) | 2022-04-12 |
| JP7749169B2 (ja) | 2025-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL285649A (en) | Azepino-indoles and other heterocyclics for the treatment of brain disorders | |
| IL290575A (en) | Preparations and methods for the treatment of disorders related to repetitive DNA | |
| IL289173A (en) | Preparations and methods for the treatment of central nervous system disorders | |
| IL275506A (en) | Preparations and methods for the treatment of central nervous system disorders | |
| IL275562A (en) | Preparations and methods for the treatment of central nervous system disorders | |
| EP4010072A4 (en) | TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES | |
| EP3746135A4 (en) | METHODS AND COMPOUNDS FOR TREATMENT OF DISEASE | |
| IL286868A (en) | Compounds and methods that monitor the expression of genes in the central nervous system | |
| EP3917620A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROCOGNITIVE DISORDERS | |
| EP3999110A4 (en) | COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISEASES | |
| IL289172A (en) | Preparations and methods for the treatment of central nervous system disorders | |
| SG11202011151VA (en) | Compositions and methods for reducing spliceopathy and treating rna dominance disorders | |
| SG11202102349PA (en) | Compositions and methods for treating disorders ameliorated by muscarnic receptor activation | |
| IL275985A (en) | Preparations and methods for the treatment of retinal disorders | |
| IL270114B1 (en) | Methods and compounds for the treatment of neurological diseases | |
| IL279634A (en) | Preparations and methods for the treatment and prevention of neurological disorders | |
| EP3979985A4 (en) | COMPOSITIONS AND METHODS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES | |
| EP3917622A4 (en) | COMPOSITIONS AND METHODS FOR TREATMENT OF DISORDERS RELATED TO ANXIETY | |
| IL287831A (en) | Oxymetazoline compounds and methods for treating eye diseases | |
| IL274067A (en) | Kinase inhibitors for the treatment of central and peripheral nervous system disorders | |
| IL286571A (en) | Compounds and methods for the treatment of neurodegenerative disorders | |
| SG11202102982QA (en) | Methods of treating myeloproliferative disorders | |
| EP3256151A4 (en) | Methods and compositions for treating muscle disease and disorders | |
| IL310559A (en) | Methods for treating disorders of the nervous system with antipurinergic substances | |
| IL311852A (en) | Preparations and methods for the treatment of neurological disorders |